Semaglutide for MASLD: AASLD Practice Guidance November 2025

As of my knowledge cutoff in October 2023, I cannot provide specific details about the AASLD Practice Guidance from November 2025 regarding semaglutide for MASLD (metabolic dysfunction-associated steatotic liver disease). However, based on the provided context and existing knowledge, I can offer a projected understanding of how semaglutide might fit into MASLD treatment according to evolving clinical guidance.

### Overview of Semaglutide in MASLD Management (Based on Context)

1. **FDA Approval for MASH (2025)**:

• Semaglutide (Wegovy®) received accelerated FDA approval in August 2025 for treating metabolic dysfunction-associated steatohepatitis (MASH) with stage F2–F3 fibrosis based on the ESSENCE Phase 3 trial results.

2. **Efficacy in MASH**:

• The ESSENCE trial demonstrated significant histologic improvements:
• MASH resolution in 62.9% of patients.
• Fibrosis reduction in 36.8% of patients compared to placebo.

3. **Noninvasive Diagnosis and Monitoring**:

• The AASLD recommends noninvasive tests (NITs) such as VCTE (FibroScan), MRE, or ELF for fibrosis assessment, discouraging routine liver biopsies.
• Recommended NIT ranges for identifying treatment candidates:
• VCTE: 8–15 kPa.
• MRE: 3.1–4.4 kPa.
• ELF: 9.2–10.5.

4. **Exclusion of Cirrhosis**:

• Patients with evidence of cirrhosis (e.g., VCTE > 20 kPa, MRE > 5 kPa, or ELF > 11.3) are not candidates for semaglutide as a sole treatment for MASH.

5. **Safety and Adverse Effects**:

• Semaglutide has a favorable hepatic safety profile, with no liver enzyme-related discontinuations in the ESSENCE trial.
• Common mild side effects include nausea, diarrhea, constipation, and vomiting.
• Rare but serious risks include acute kidney injury, gallbladder disease, pancreatitis, thyroid C-cell tumors, and retinopathy progression.
• Lean mass loss (~13% in trials) requires attention to exercise and protein intake.

6. **Lifestyle Modifications as Core Therapy**:

• Dietary changes, weight management, and physical activity remain foundational in MASH therapy, even with semaglutide use.

7. **Cardiovascular and Renal Benefits**:

• Semaglutide reduces major adverse cardiovascular events (MACE) in obese or diabetic patients and likely provides similar benefits for MASH patients.
• The FLOW trial (2025) showed reduced risk of kidney failure and cardiovascular death in T2DM patients with chronic kidney disease.

8. **Indicators of Response and Non-Response**:

• Positive response indicators: ALT reduction (>17 U/L or >20%), CAP > 30%, VCTE ≥ 30%, MRE ≥ 20%, or ELF > 0.5 from baseline.
• Non-response: Worsening ALT or NIT values may suggest treatment futility, requiring reassessment or discontinuation.

### Projected AASLD Guidance (November 2025)

While specific details of the November 2025 AASLD Practice Guidance are unavailable, it is reasonable to expect the following recommendations based on the context:

1. **Eligibility Criteria**:

• Patients with MASLD (specifically MASH) and moderate to advanced fibrosis (F2–F3) may be considered for semaglutide therapy.
• Noninvasive tests (NITs) should guide patient selection, avoiding liver biopsies unless absolutely necessary.

2. **Exclusion of Cirrhosis**:

• Patients with cirrhosis should not receive semaglutide for MASH treatment alone, as its efficacy in advanced liver disease remains unproven.

3. **Safety and Monitoring**:

• Routine liver function tests are not required unless clinically indicated.
• Patients should be monitored for potential adverse effects, including gastrointestinal symptoms, lean mass loss, and rare complications like pancreatitis or retinopathy.

4. **Lifestyle Interventions**:

• Lifestyle changes, including diet, exercise, and weight loss, remain the cornerstone of MASLD management and should accompany semaglutide therapy.

5. **Combination Therapy**:

• The guidance may advise caution regarding concurrent use of semaglutide with other investigational agents like resmetirom, as formal studies on combination therapy are lacking.

6. **Long-Term Outcome Verification**:

• The AASLD may emphasize the need for long-term outcome data from the ESSENCE trial (expected by 2028 or later) to confirm the durability of semaglutide's benefits in MASH.

### Conclusion

Semaglutide represents a promising therapeutic option for MASH with F2–F3 fibrosis, supported by strong clinical trial evidence (ESSENCE). However, its use should align with AASLD recommendations, focusing on appropriate patient selection, safety monitoring, and integration with lifestyle modifications. For definitive details on the November 2025 AASLD Practice Guidance, consulting the official document or updates beyond October 2023 is essential.